References

Antimicrobial and antioxidant properties of chitosan and its derivatives and their applications: a review

10.1016/j.ijbiomac.2020.08.153 · 2020 · External reference

Controlled curcumin delivery via carboxymethyl starch-modified gamma alumina nanoparticles in a polyethylene glycol-based hydrogel

10.1002/app.55946 · 2024 · External reference

Sjögren’s syndrome. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology

2022 · External reference

Multimodal single-cell sequencing of B cells in primary Sjögren’s syndrome

10.1002/art.42683 · 2024 · External reference

Sjögren syndrome

10.1038/nrdp.2016.47 · 2016 · External reference

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

10.1371/journal.pone.0179431 · 2017 · External reference

Regulatory T cell therapy promotes TGF-β and IL-6-dependent pro-inflammatory Th17 cell generation by reducing IL-2

10.1038/s41467-025-62628-7 · 2025 · External reference

An essential role for the IL-2 receptor in treg cell function

10.1038/ni.3540 · 2016 · External reference

Cytokine couture: designer IL2 molecules for the treatment of disease

10.2147/itt.s500229 · 2025 · External reference

Green synthesis of metal nanocarriers: a perspective for targeting glioblastoma

10.1016/j.drudis.2024.104219 · 2024 · External reference

The multiple roles of B cells in the pathogenesis of Sjögren’s syndrome

10.3389/fimmu.2021.684999 · 2021 · External reference

Salivary gland epithelial cells from patients with Sjögren’s syndrome induce B-lymphocyte survival and activation

2020 · External reference

A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models

10.1172/jci173107 · 2024 · External reference

Pulmonary manifestations of Sjögren’s syndrome

10.1183/16000617.0011-2016 · 2016 · External reference

A function for interleukin 2 in Foxp3-expressing regulatory T cells

10.1038/ni1263 · 2005 · External reference

Infertility treatment using polysaccharides-based hydrogels: new strategies in tissue engineering and regenerative medicine

10.1186/s12951-025-03267-4 · 2025 · External reference

Efficacy and safety of low-dose interleukin 2 for primary Sjögren syndrome: a randomized clinical trial

10.1001/jamanetworkopen.2022.41451 · 2022 · External reference

Ex vivo enhancement of CD8+ T cell activity using functionalized hydrogel encapsulating tonsil-derived lymphatic endothelial cells

10.7150/thno.100079 · 2025 · External reference

Polysaccharide hydrogels based on cellulose and chitosan for drug sustained-release applications

2025 · External reference

Sphingosine-1-phosphate alleviates Sjögren’s syndrome-like symptoms via inducing autophagy and regulating status of Treg cells in NOD mice

2024 · External reference

An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice

10.1126/sciimmunol.aba5264 · 2020 · External reference

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

10.1038/nri3823 · 2015 · External reference

Exploiting a natural conformational switch to engineer an interleukin-2 “superkine”

10.1038/nature10975 · 2012 · External reference

Designing hydrogels for controlled drug delivery

10.1038/natrevmats.2016.71 · 2016 · External reference

Injectable biodegradable Chitosan–PEG/PEG–Dialdehyde hydrogel for stem cell delivery and cartilage regeneration

10.3390/gels10080508 · 2024 · External reference

Hydrogel systems for spatiotemporal controlled delivery of immunomodulators: engineering the tumor immune microenvironment for enhanced cancer immunotherapy

10.3389/fcell.2024.1514595 · 2024 · External reference

Preparation and biocompatibility of core-shell microspheres for sequential, sustained release of BMP-2 and VEGF

10.1155/2022/4072975 · 2022 · External reference

Interleukin-2 receptor signaling: at the interface between tolerance and immunity

10.1016/j.immuni.2010.08.004 · 2010 · External reference

Sjögren’s syndrome

10.1146/annurev-pathol-012513-104728 · 2014 · External reference

Sjögren’s syndrome: old and new therapeutic targets

10.1016/j.jaut.2019.102364 · 2020 · External reference

Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren’s syndrome

10.1136/annrheumdis-2018-213036 · 2018 · External reference

Progress in chitin/chitosan and their derivatives for biomedical applications: where we stand

10.1016/j.carbpol.2024.122233 · 2024 · External reference

Biomedical exploitation of chitin and chitosan via mechano-chemical disassembly, electrospinning, dissolution in imidazolium ionic liquids, and supercritical drying

10.3390/md9091510 · 2011 · External reference

Sjögren’s syndrome: a systemic autoimmune disease

10.1007/s10238-021-00728-6 · 2022 · External reference

Sciatic nerve injury regeneration in adult male rats using gelatin methacrylate (GelMA)/poly(2-ethy-2-oxazoline) (PEtOx) hydrogel containing 4-aminopyridine (4-AP)

10.1002/jbm.a.37514 · 2023 · External reference

Th17 and regulatory T cell balance in autoimmune and inflammatory diseases

10.1016/j.autrev.2013.12.004 · 2014 · External reference

The role of interleukin-2 during homeostasis and activation of the immune system

2012 · External reference

Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity

10.1038/s41598-021-87102-4 · 2021 · External reference

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease

10.1016/j.jaut.2018.10.017 · 2018 · External reference

PEG-modified Fe2O3 coated agarose hydrogel: a synthesized nanocomposite for regulated 5-fluorouracil delivery

10.1016/j.ijbiomac.2024.133900 · 2024 · External reference

Nano-based drug delivery system for therapeutics: a comprehensive review

10.1088/2057-1976/acedb2 · 2023 · External reference

T follicular helper cells and T follicular regulatory cells in autoimmune diseases

10.3389/fimmu.2023.1178792 · 2023 · External reference

Advances in cellular and molecular pathways of salivary gland damage in Sjögren’s syndrome

10.3389/fimmu.2024.1405126 · 2024 · External reference

EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies

10.1136/annrheumdis-2019-216114 · 2020 · External reference

The alterations in and the role of the Th17/treg balance in metabolic diseases

2021 · External reference

FOXP3+ regulatory T cells in the human immune system

10.1038/nri2785 · 2010 · External reference

Precision nanophytomedicine: alginate-chitosan nanogels encapsulating Olea ferruginea ethyl acetate fraction for enhanced cardiovascular protection

10.1016/j.ijbiomac.2025.144656 · 2025 · External reference

2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for primary Sjögren’s Syndrome: a consensus and data-driven methodology involving three international patient cohorts

10.1002/art.39859 · 2017 · External reference

Enhanced local delivery of engineered IL-2 mRNA by porous silica nanoparticles to promote effective antitumor immunity

10.1021/acsnano.3c06733 · 2023 · External reference

Current trends in smart mesoporous silica-based nanovehicles for photoactivated cancer therapy

10.1016/j.jconrel.2021.10.005 · 2021 · External reference

Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjog̈ren’s syndrome

10.1038/s41392-022-01103-x · 2022 · External reference

IFN-γ-producing TH1 cells and dysfunctional regulatory T cells contribute to the pathogenesis of Sjögren’s disease

2024 · External reference

Microneedle-mediated delivery of immunomodulators restores immune privilege in hair follicles and reverses immune-mediated alopecia

10.1002/adma.202312088 · 2024 · External reference

Pathogenesis and treatment of Sjogren’s syndrome: review and update

10.3389/fimmu.2023.1127417 · 2023 · External reference